AZ and the Karolinska Institute create new research center for cardiometabolic and regenerative med development
Twice in one day, AstraZeneca PLC announced plans to boost the company’s drug development efforts for cardiometabolic diseases. The first was with Moderna Therapeutics, and the second, with long-time partner the Karolinska Institute, additionally focuses on regenerative medicine.
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com